The funding will help several initiatives including patient follow-up with trials, opening a research and development center in Dallas and completing a facility in Geneva, Switzerland, according to a news release.
The company completed enrollment for the U.S. investigational device exemption trial with the Baguera C cervical disc implant, according to a Feb. 29 announcement. The trial will compare Baguera C in single-level cervical disc replacement to ZimVie’s Mobi-C.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
